Latest news with #BIAF
Yahoo
29-05-2025
- Business
- Yahoo
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane. The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics. A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients. The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation. BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services. While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane. The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics. A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients. The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation. BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services. While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
20-05-2025
- Business
- Yahoo
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
Shares of bioAffinity Technologies, Inc. BIAF have risen 0.04% since the company reported its earnings for the quarter ended March 31, 2025, slightly lagging the broader market, as the S&P 500 Index rose 1.1% over the same period. However, the stock's longer-term performance has been notably weak, with a 54.7% decline over the past month compared to a robust 15.4% increase in the S&P 500. For the first quarter of 2025, bioAffinity reported revenues of $1.9 million, down 22.9% from $2.4 million in the year-ago period. The decline was primarily due to changes in revenue contributions from patient service fees, histology services and medical director fees. Despite the top-line contraction, BIAF's net loss narrowed on a per-share basis to $0.16 compared with a net loss of $0.20 per share in the first quarter of 2024, though the absolute loss widened to $2.7 million from $1.9 million due to a higher share count. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Operating expenses increased 2.9% to $4.5 million from $4.4 million in the prior-year quarter. Direct costs and expenses declined 13.1% to $1.4 million from $1.6 million, and R&D expenses fell 6.7% to $367,386 from $393,639. However, clinical development expenses rose sharply from $48,960 to $138,353, reflecting ongoing investments in bioAffinity's pivotal trial strategy. Selling, general and administrative expenses increased 12.2% to $2.5 million from $2.2 million, as the company scaled its commercialization team for CyPath Lung. Sales of bioAffinity's flagship diagnostic, CyPath Lung, surged 276% year over year, reflecting growing market acceptance and operational scaling following the test's 2024 beta launch in Texas. The company emphasized strong demand during the quarter, supported by more than 600 tests delivered in 2024 and continued momentum into 2025. Management attributed the performance to the test's clinical utility, including its ability to detect early-stage lung cancer and prevent unnecessary invasive procedures. The sharp revenue decline appears at odds with the CyPath Lung sales spike, likely indicating a strategic pivot away from low-margin services. This aligns with management's decision to discontinue select pathology services and implement cost-cutting measures expected to save approximately $3.8 million annually. These actions are designed to improve profitability and focus resources on high-margin diagnostics. bioAffinity Technologies, Inc. price-consensus-eps-surprise-chart | bioAffinity Technologies, Inc. Quote CEO Maria Zannes highlighted bioAffinity's operational progress and strategic direction in her remarks. She pointed to a clear focus on commercial execution, including targeted labor reductions and operational changes at the company's subsidiary lab. These efforts are aimed at supporting CyPath Lung's growth while improving the overall cost structure. Zannes also emphasized recent enhancements in CyPath Lung's test processing. Specifically, post-quarter improvements increased data acquisition throughput by 50% and reduced per-test cost by more than 25%, materially enhancing scalability and profitability without compromising clinical performance. bioAffinity ended the quarter with $0.4 million in cash, down from $1.1 million as of Dec. 31, 2024. However, the company has since bolstered its liquidity position, raising $1.4 million through warrant exercises in February and an additional $3.3 million via a public offering in May. These capital raises are expected to support commercialization efforts and ongoing clinical development. bioAffinity did not provide forward-looking financial guidance. However, qualitative commentary suggested a continued strategic pivot toward diagnostics and ongoing expansion of CyPath Lung's market presence. In addition to financial and operational updates, bioAffinity reported progress in strengthening its intellectual property portfolio. During the quarter, the company received acceptance of a patent application from the Australian Patent Office for CyPath Lung. This development enhances the test's international commercialization potential and broadens BIAF's global IP footprint. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report bioAffinity Technologies, Inc. (BIAF): Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Korea Herald
18-04-2025
- Entertainment
- Korea Herald
Director Joung Yu-mi's 'Glasses' invited to Cannes Film Festival
Animated film marks only Korean film invited to Cannes so far Director Joung Yu-mi's short animated film 'Glasses' has been invited to compete in the short film category at the 78th Cannes Film Festival, making it the only South Korean work selected for this year's prestigious event so far. 'Glasses' will be showcased in the Critics' Week short film competition, a parallel section of the Cannes Film Festival dedicated to highlighting emerging voices in global cinema. The 15-minute animation follows Yu-jin, who, after breaking her glasses, visits an optician. During her eye exam, she envisions a house in a field and finds herself transported inside. There, she encounters three shadow versions of herself, reconciles with them, and emerges with a new outlook on life -- symbolized by a new pair of glasses. The film is entirely without dialogue. 'Each of us has an inner child, like a little kid living inside our hearts. This inner child stays with us like a shadow, but we often fail to recognize its presence. We go through life having forgotten about this child, only to encounter it again in the darker corners of our lives," she said, via a statement released by Bucheon International Animation Festival on Friday. BIAF supported the production of the animation film. "The inner child represents the protagonist's unconsciousness — a space in the heart where repressed emotions, wounds and complexes gather, visualized as a shadow," she said, adding, "The story aims to portray a journey in which, after encountering three shadows one by one inside the home, the protagonist steps outside, receives a new pair of glasses, and begins to face and reconcile with her own shadows." 'Glasses' stands as the first Korean project invited to this year's Cannes Film Festival. Notably, no Korean films were selected for either the main competition or noncompetitive sections this year -- marking the first absence of Korean films in 26 years. This year, several Korean entries were submitted to the film festival, including 'The Ugly' by "Train to Busan" director Yeon Sang-ho, 'The Journey to Gyeongju' by Kim Mi-jo, and 'Omniscient Reader' by Kim Byung-woo. Oscar-winning auteur Park Chan-wook's anticipated new film 'No Other Choice' was reportedly not submitted due to incomplete postproduction. The Cannes Film Festival will be held in Cannes, France, May 13-24.
Korea Herald
21-03-2025
- Entertainment
- Korea Herald
BIAF 2025 opens submissions
South Korea's premier animation festival continues to cement global standing with Academy Award qualifying status The Bucheon International Animation Festival (BIAF) has kicked off its submission period for its 27th edition, scheduled to run October 24-28. The festival is accepting works completed after Jan. 1, 2024 that haven't previously screened at BIAF. Deadlines vary by category: June 30 for shorts (including student films, TV and commissioned works and Korean shorts) and July 31 for features. The festival will distribute awards across 16 categories in the International Competition section. BIAF's profile has jumped significantly in recent years largely thanks to its Academy Award qualifying status, which runs through September 2027. The Grand Prize winner in the short film category automatically becomes eligible for Oscar consideration — a coveted pathway for animators worldwide. Recent selections from the festival have demonstrated this Oscar pipeline in action. "Memoirs of a Snail" (Adam Elliot), which had its Asian premiere at BIAF 2024 and took home the Grand Prize in the feature category, landed a 2025 Academy Award nomination for Best Animated Film. Similarly, "Wander to Wonder," which snagged BIAF's Jury Prize for Short Film, earned a Best Animated Short Film nomination at the 2025 Academy Awards. Beyond its Oscar connections, BIAF has established itself as a crucial platform for introducing internationally acclaimed animation to Korean audiences. The 2023 edition featured several high-profile works making their Korean premiere, including "Chicken for Linda!" (winner of the Annecy International Animation Film Festival Grand Prize), "Robot Dreams" (a 2023 Cannes selection and 2024 Oscar nominee that served as BIAF's opening film), and "Art College 1994," which premiered in competition at the 73rd Berlin International Film Festival. The festival offers comprehensive programming beyond competitions, with special screenings and industry events that attract animation professionals and enthusiasts from across the globe. Selected shorts will be announced in August, while feature selections will follow in September on the festival's official website. Submissions can be made through the festival's website or FilmFreeway.
